Bouchaud O, Plique O, Ruggeri C, Saimot AG, Coulaud JP; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 446 (abstract no. PO-B19-1863).
Tropical and infectious diseases department, Bichat Cl. Bernard Hospital, Paris, France.
In HIV patients, chronic diarrhea is frequent and difficult to control. We performed a controlled double blind versus placebo pilot study to assess the efficiency of diosmectite in severe chronic diarrhea (5 and more bowel movements/day) with no curable etiology. Placebo (P) and diosmectite (D) at the dosage of 9 gr x 3/day were randomly allocated for a duration of 10 days. A switch to the active drug (D) was possible at day 5. RESULTS: 19 patients were included: 9 in the P group, 10 in the D group. Mean CD4 cells was 67/mm3 (3-323). At day 0, the average of bowel movements was 6.3 (5-10). At day 5, all the patients in the P group have switched to the active drug versus 50% in the D group (p = 0.014). From day 5 do day 10, all the patients were treated with D. At day 10, a highly significant reduction (51%) in the number of bowel movements (mean: 3.1) was observed (p < 0.001). Except for 1 case of constipation, no adverse event was observed. CONCLUSION. Diosmectite (27 gr/day) appears to be safe and highly effective in the treatment of severe chronic diarrhea in severely HIV immuno-compromised patients.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Constipation
- Defecation
- Diarrhea
- Double-Blind Method
- HIV Infections
- HIV Seropositivity
- Humans
- Pilot Projects
- Silicates
- Smectite
Other ID:
UI: 102204830
From Meeting Abstracts